Mikhail Eydelman sold $320K of Vaxcyte (PCVX)

Executed Feb 5 2025, disclosed Feb 7 2025, 2 days later.

Value, as filed

$320K

3,539 sh across 2 lots

Executed

Feb 5 2025

the trade date, as filed

Disclosed

Feb 7 2025

2 days after the trade

Return, 21 sessionsiFrom the disclosed entry session; derived

–

purchases only

Returns are measured on stock purchases only.

The filer

Mikhail Eydelman SVP, GEN COUNSEL & CORP SEC profile →

Mikhail Eydelman (SVP, GEN COUNSEL & CORP SEC) filed 7 Form 4 reports in the past 24 months (0 purchases, 7 sales), most often in Vaxcyte, Inc. (PCVX). The largest single filing was $628K of PCVX (5,500 sh across 3 lots, as filed), executed Oct 1 2024.

The name

PCVX

Vaxcyte, Inc. PCVX · Healthcare · 41 filings in 24 months ticker →

Healthcare · Vaxcyte, Inc., a clinical-stage vaccine innovation company, develops conjugate and novel protein vaccines to prevent or treat bacterial inf…

More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→

Other filings by Mikhail Eydelman in PCVX

PCVXSALE Vaxcyte, Inc. $346K
4,888 sh across 2 lots
Exec Mar 5 2025
Filed Mar 7 2025 · 5:30 PM ET PCVXSALE Vaxcyte, Inc. $336K
3,921 sh × $85.73
Exec Jan 6 2025
Filed Jan 7 2025 · 5:30 PM ET PCVXSALE Vaxcyte, Inc. $421K
4,612 sh across 2 lots
Exec Dec 5 2024
Filed Dec 9 2024 · 5:30 PM ET PCVXSALE Vaxcyte, Inc. $449K
4,212 sh across 3 lots
Exec Nov 5 2024
Filed Nov 6 2024 · 5:30 PM ET PCVXSALE Vaxcyte, Inc. $453K
4,143 sh across 2 lots
Exec Oct 7 2024
Filed Oct 8 2024 · 5:30 PM ET PCVXSALE Vaxcyte, Inc. $628K
5,500 sh across 3 lots
Exec Oct 1 2024
Filed Oct 3 2024 · 5:30 PM ET